ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,042.66
-0.07%
US Tech 100
20,618.00
0.03%
다우존스 지수
44,676.29
-0.24%
Bitcoin
95,340.63
-0.54%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. USOTC

  6. Ayala Pharmaceuticals Inc (CE) (ADXS) 시세

Ayala Pharmaceuticals Inc (CE)

Ayala Pharmaceuticals Inc (CE) (ADXS)

USOTC
0.1051
0.00
( 0.00% )
업데이트: 09:00:00
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
0.1051
매수가
0.00
매도가
0.00
거래량
3
0.00 일간 변동폭 0.00
0.0012 52주 범위 1.49
market_cap
4.481M
전일 종가
0.1051
개장가
-
최근 거래 시간
1
@
0.027
마지막 거래 시간
03:13:14
재정 규모
-
VWAP
-
평균 볼륨(3m)
2,049
발행 주식
42,633,400
배당수익률
-
주가수익률
-0.10
주당순이익(EPS)
-1.13
매출
13k
순이익
-48.07M

Ayala Pharmaceuticals Inc (CE) 정보

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer ... Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.ayalapharma.com
본부
Wilmington, Delaware, USA
설립됨
-
Ayala Pharmaceuticals Inc (CE) is listed in the Pharmaceutical Preparations sector of the OTC 시장 with ticker ADXS. The last closing price for Ayala Pharmaceuticals (CE) was US$0.11. Over the last year, Ayala Pharmaceuticals (CE) shares have traded in a share price range of US$ 0.0012 to US$ 1.49.

Ayala Pharmaceuticals (CE) currently has 42,633,400 shares in issue. The market capitalisation of Ayala Pharmaceuticals (CE) is US$4.48 million. Ayala Pharmaceuticals (CE) has a price to earnings ratio (PE ratio) of -0.10.

ADXS 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

06 3월 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 3월 2024
Edgar (US Regulatory)

Form DEFM14C - Definitive information statement relating to merger or acquisition

05 3월 2024
Edgar (US Regulatory)

Form 8-K - Current report

24 2월 2024
Edgar (US Regulatory)

Form PREM14C - Preliminary information statements relating to merger or acquisition

21 2월 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

15 2월 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

13 2월 2024
Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

13 2월 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

12 2월 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 2월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.0781289.2592592590.0270.10510.02771350.08520103CS
40.07805288.539741220.027050.10510.02726760.0648838CS
120.0851425.50.020.10510.0220490.05794076CS
26-0.1449-57.960.250.30990.001241850.16056647CS
52-0.6949-86.86250.81.490.0012119700.70747941CS
156-4.8849-97.89378757524.994.990.00121579990.17606943CS
260-0.0299-22.14814814810.1354.990.00121568470.17606943CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AOLSAeolus Pharmaceuticals Inc (CE)
US$ 0.005
(499,900.00%)
385
IPTKAS IP Tech Inc (CE)
US$ 0.0018
(179,900.00%)
1,000
VIVEViveve Medical Inc (CE)
US$ 0.0005
(49,900.00%)
23.11k
IDBHFIndustrias Bachoco SAB De CV (CE)
US$ 0.0161
(16,000.00%)
600
BTTXBetter Therapeutics Inc (CE)
US$ 0.0001
(9,900.00%)
165.33k
FDVXFFenixOro Gold Corporation (CE)
US$ 0.000001
(-100.00%)
6k
PLBLFAltus Copper Corporation (CE)
US$ 0.000001
(-99.93%)
100
BZTGBuzz Technologies Inc (CE)
US$ 0.000001
(-99.80%)
2.58M
ARBHArboreta Healthcare Inc (CE)
US$ 0.000001
(-99.67%)
2k
APQTAppliqate Inc (CE)
US$ 0.000001
(-99.50%)
4k
HMBLHUMBL Inc (PK)
US$ 0.0003
(0.00%)
274.12M
FUNRFunr (PK)
US$ 0.0004
(300.00%)
173.33M
RDARRaadr Inc (PK)
US$ 0.001
(-9.09%)
116.32M
BEGIBlackStar Enterprise Group Inc (PK)
US$ 0.0008
(-42.86%)
105.07M
TSOITherapeutic Solutions International Inc (PK)
US$ 0.0004
(-11.11%)
75.02M

ADXS Discussion

게시물 보기
willlbone willlbone 7 월 전
Form 15, to de-register.
👍️0
James salmon James salmon 9 월 전
Sorry I keep putting IMNU I mean IMNM
👍️0
James salmon James salmon 9 월 전
Well IMNU holding just hit $60 million or there abouts.
👍️0
James salmon James salmon 10 월 전
Actually make that $50 million at todays IMNU price
👍️0
James salmon James salmon 10 월 전
Agree they hold over well $40 million in IMNU stock
👍️0
willlbone willlbone 10 월 전
Under 70 cent is a bargain.
👍️0
ignatiusrielly35 ignatiusrielly35 10 월 전
Aye aye. Good luck with it.
👍️0
James salmon James salmon 10 월 전
Looking at filing I think the deal will close very quickly as most of the shares are held by a few investors or funds, I see Feb 8th mentioned in the filing for funds to approve.
👍️0
ignatiusrielly35 ignatiusrielly35 10 월 전
Well the market obviously likes the deal.
👍️0
James salmon James salmon 10 월 전
I wish it was mine but talking about the increase ADXS has seen in its holding of IMNU stock, when deal goes through.
👍️0
ignatiusrielly35 ignatiusrielly35 10 월 전
Nice work, James.
👍️0
James salmon James salmon 10 월 전
Well IMNU just hit $25, so that $30 million just became $54 million on paper in stock.
👍️0
ANTI-BAGHOLDER ANTI-BAGHOLDER 10 월 전
Only 3 milly floater too. :)
👍️0
Bigstud is here Bigstud is here 10 월 전
What price did u bought them at?
👍️0
James salmon James salmon 10 월 전
I just noticed the actual amount of shares ADXS will get, it’s 2,175,489 shares which at $22 a share which is IMNU current share price that is $48 million.

ADXS got the shares at $13.79 in this deal disclosed today.

Add the $20 million in cash and $37 million in milestones.

ADXS current market cap is just under $15 million.

For the first time in a longtime I can say ADXS is cheap, very cheap.
👍️0
James salmon James salmon 10 월 전
Well snagged a few thousand at open, no brainer with news this morning.
👍️0
James salmon James salmon 10 월 전
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile


BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval.
👍️0
AJ Freely AJ Freely 1 년 전
$ADXS - Ayala Pharmaceuticals to Merge w/ Biosight Ltd, a privately-held pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders
To close prior to Q3 23
Float under 5 m
👍️0
AJ Freely AJ Freely 1 년 전
$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24
👍️0
AJ Freely AJ Freely 1 년 전
$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24
👍️0
island man island man 1 년 전
Hi GF
Check Qbts And Rxrx could move soon
👍️0
island man island man 1 년 전
Hi GF
Into Qbts and some bzfd with a sprinkle of Rxrx could be riding a wave 🍾🍾👍👍
👍️0
Renee Renee 1 년 전
Advaxis Inc. changed to Ayala Pharmaceuticals Inc.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
James salmon James salmon 2 년 전
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose)

Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper and sustained treatment responses

Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally.

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced updated results from Phase 2 (Part A segment) of the RINGSIDE study evaluating AL102 in desmoid tumors. The results are summarized in an abstract published today for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. More detailed results will be featured in a poster session at ASCO on Saturday, June 3. AL102 is a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI).
👍️0
hdwrsft hdwrsft 2 년 전
The only safe haven for $$$$ these days seems to be under the mattress.
👍️0
Ryguy008 Ryguy008 2 년 전
What a turd. CEO Ken is running this into the ground with his carelessness.

$ADXS
👍️0
hdwrsft hdwrsft 2 년 전
Another massive bank shockingly failed. One day it's biz as usual, the next day, total implosion. Banking customers freaking the fvck out.

Omg. Geez. I know how that feels...like right after that first massive R/S. At that point, subsequent R/S further obliterated what little was left.

Expensive lesson of the game for sure. All the wiser.

The banking news this week makes the losses suffered over the many years in this next of the woods look like shriveled mouse nuts.




👍️0
hdwrsft hdwrsft 2 년 전
Just think, in just another 7 years, and who knows how many more R/S between now and then, this biz will have somehow survived, what???

Will it be THREE DECADES???

OMG.

Enuff said....

👍️0
HereToFightScams HereToFightScams 2 년 전
If there is any justice in this universe, both Ken the sleasebag lawyer and Sidransky the supposed doctor with no patients and primary allegiance to his Israeli hedge fund companies, will spend the next decade or so in prison to account for their sins.
👍️0
carp77 carp77 2 년 전
Looks like things are picking up we may surpass 1000 bucks in total trades today
👍️0
James salmon James salmon 2 년 전
Well it’s certainly been a learning experience. I would not say broke as I sold enough on the run to $30 to cover my initial investment and some. I left a lot on the table and could have been set up nicely if I had sold all.

I have made some up on other stocks and one thing I learned was to spread the money around and not be over invested in 1 stock.
👍️0
oakrock oakrock 2 년 전
James, Are you as broke as I am from ADXS?
👍️0
hdwrsft hdwrsft 2 년 전
Hmm (Glancing at the EOY PPS).

Some things never change.

👍️0
hdwrsft hdwrsft 2 년 전
Them pesty R/S's pop up quicker than weeds at springtime in these parts.
👍️0
ADXSINC ADXSINC 2 년 전
Waiting patiently for the next 20 for 1 reverse split.......
👍️0
hdwrsft hdwrsft 2 년 전
Crickets.
👍️0
Traderbx Traderbx 2 년 전
I see alot of same names (fellow bag holders) still posting here… anyone recovered their ADXS losses from elsewhere yet?
👍️0
hdwrsft hdwrsft 2 년 전
The last of someones FTX crypto currency investdonation......?
👍️0
girlfriend girlfriend 2 년 전
Salmon man adding?
👍️0
ADXSINC ADXSINC 2 년 전
That was blue eyes, she is still buying
👍️0
hdwrsft hdwrsft 2 년 전
Volume posted this early AM:

"1"


Totally laughable.
👍️0
ubmmg ubmmg 2 년 전
Not sure what data you are referring to. Is it this:"ADXS-503: Phase 1/2 combination with KEYTRUDA updated clinical and immune/biomarker data for KEYTRUDA failures and initial readout in first-line patients"? Haven't been following this POS for some time...
👍️0
phytokaiser1 phytokaiser1 2 년 전
Hi Nick,

So my Ph.D. is in plant biology (breeding and natural products), but I actually worked in a medicinal chemistry lab modifying natural products for improved pharmacological function. I own multiple patents on plants that have improved phenotypic characteristics.

I bring this up, because I know a lot about fungi and psilocybin. Personally, I think Lions Mane is the most valuable fungi due to its neuroregenerative properties. However, psilocybin seems to be incredibly promising in addiction and end of life care. I haven't looked at the landscape, but I know Peter Thiel backed this pharma company.

https://atai.life/

They are on a huge hiring spree at the moment for senior level members.

https://boards.greenhouse.io/atai
👍️0
Nickwvt Nickwvt 2 년 전
I'm hearing a lot of chatter about psylocybin mushrooms being used for medicinal purposes. Don't know if that fits into your area of expertise or not.....just throwing it out there
👍️0
phytokaiser1 phytokaiser1 2 년 전
Thanks man, much appreciated. Good luck and stay safe.
👍️0
ignatiusrielly35 ignatiusrielly35 2 년 전
Don’t give up, Phyto. Network, and talk to as many people as possible. You never know where an idea may come from. All of my best to you.
👍️0
phytokaiser1 phytokaiser1 2 년 전
Thanks and ya, it has been difficult but thanks for your thoughts. I have been looking at head hunters but they have told me multiple times that they do not utilize scientists in the way I want to work lol. But I will keep trying.

Good news on AVXL, thanks for the heads up years ago!
👍️0
ignatiusrielly35 ignatiusrielly35 2 년 전
Gee, I’m not sure on that one, phyto. Nothing immediately comes to mind as to investment firms that might need expertise in plant biology to analyze investments. If it was biochemistry, different story, obviously. I’m not even sure if commodities outfits use plant biologists to analyze crop supply, such as wheat FCOJ, etc. Maybe you should research some headhunters who specialize in financial analysts. Clearly they would want you for your scientific knowledge and not as an actual financial analyst.

Congrats on your PhD! Big achievement!
👍️0
phytokaiser1 phytokaiser1 2 년 전
Hey!

It's good to talk to you again. I kind of took a break from stocks and investing over the past few years. Got my PhD (Finally) and went to work. The crash of ONVO and ADXS sucked so I was watching stocks from a distance (Though I made a little on AMC lol).

I actually wanted to pick your brain a little and ask for some advice. I got a PhD in plant biology and was wondering how I could enter the financial markets with this since I don't have a lot of formal training in the sector. It is definitely something I am interested in but am having trouble breaking in/getting interviews.

Good talking to you again, let me know if you want me to review any technical aspects for anything, feels good to be back on the boards.
👍️0
ignatiusrielly35 ignatiusrielly35 2 년 전
If the data are good it will hit resistance at 40. My prediction and I’m sticking with it. They’ll allow it to that point as an inflection, then the takedown. Is there any logic involved? No. They don’t need logic.

It’s a guess.

Data bad? Unlikely. But if it’s mixed they will still allow it to hit 40, then they will take it down.
👍️0

최근 히스토리

USOTC
ADXS
Ayala Pharmaceuticals (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유